Targeting Cox-2 by siRNA or small molecule inhibitors effectively inhibits cell viability, migration and invasion, tumor growth, and reverses chemoresistance in preclinical models of OC (Gu et al., 2008; Deng et al., 2020). This evidence concerns the gene PTGS2 and neoplasm.